Analysis of deoxycytidine accumulation in gemcitabine treated patients

Nucleosides, Nucleotides and Nucleic Acids

Volumn 25, Issue 9-11, 2006, Pages 1225-1232

  Honeywell, R ^a   Van Groeningen, C J ^a   Laan, A C ^a   Strocchi, E ^b   Ruiter, R ^a   Giaccone, G ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Deoxycytidine; Gemcitabine; Pharmacokinetics; Tandem mass spectrometry

Indexed keywords

ACETIC ACID ETHYL ESTER; DEOXYCYTIDINE; GEMCITABINE;

ARTICLE; CHROMATOGRAPHY; HUMAN; PRECIPITATION; TANDEM MASS SPECTROMETRY;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CHEMISTRY, CLINICAL; CHROMATOGRAPHY; DEOXYCYTIDINE; HUMANS; MASS SPECTROMETRY; MODELS, BIOLOGICAL; MODELS, CHEMICAL; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 33750454481     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770600894642     Document Type: Article

References (11)

1. Arner, E.S.; Eriksson, S. Mammalian deoxyribonucleoside kinases. Pharmacol. Ther. 1995, 67, 155-186.
2. Peters, G.J.; Ackland, S.P. New antimetabolites in preclinical and clinical development. Expert. Opin. Investig. Drugs 1996, 5, 637-679.
3. Plunkett, W.; Huang, P.; Searcy, C.E.; Gandhi, V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin. Oncol. 1996, 23, 3-15.
4. Van Moorsel, C.J.; Bergman, A.M.; Veerman, G.; Voorn, D.A.; Ruiz van Haperen, V.W.; Kroep, J.R.; Pinedo, H.M.; Peters, G.J. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines. Biochim. Biophys. Acta. 2000, 1474, 5-12.
5. Kroep, J.R.; Giaccone, G.; Voorn, D.A.; Smit, E.F.; Beijnen, J.H.; Rosing, H.; Van Moorsel, C.J.; van Groeningen, C.J.; Postmus, P.E.; Pinedo, H.M.; Peters, G.J. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J. Clin. Oncol. 1999, 17, 2190-2197.
6. Ruiz van Haperen, V.W.; Veerman, G.; Vermorken, J.B.; Peters, G.J. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem. Pharmacol. 1993, 46, 762-766.
7. Baker, C.H.; Banzon, J.; Bollinger, J.M.; Stubbe, J.; Samano, V.; Robins, M.J.; Lippert, B.; Jarvi, E.; Resvick, R. 2′-Deoxy-2′- methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J. Med. Chem. 1991, 34, 1879-1884.
8. Heinemann, V.; Xu, Y.Z.; Chubb, S.; Sen, A.; Hertel, L.W.; Grindey, G.B.; Plunkett, W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol. Pharmacol. 1990, 38, 567-572.
9. Goan, Y.G.; Zhou, B.; Hu, E.; Mi, S.; Yen, Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2- difluorodeoxycytidine in the human KB cancer cell line. Cancer Res. 1999, 59, 4204-4207.
10. Heinemann, V.; Xu, Y.Z.; Chubb, S.; Sen, A.; Hertel, L.W.; Grindey, G.B.; Plunkett, W. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res. 1992, 52, 533-539.
11. Plunkett, W.; Huang, P.; Xu, Y.Z.; Heinemann, V.; Grunewald, R.; Gandhi, V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin. Oncol. 1995, 22, 3-10.